新鳳鳴(603225.SH):子公司中維化纖擬向其控股子公司增資
格隆匯1月20日丨新鳳鳴(603225.SH)公佈,根據公司戰略發展目標和需要,公司全資子公司中維化纖和臨杭新市開發建設按持股比例共同向鴻益熱電新增18,000萬元人民幣註冊資本,新增註冊資本後鴻益熱電註冊資本變更為33,000萬元。中維化纖增資17,100萬元,其中以實物方式增資15,354.05萬元,以其他方式增資159.810089萬元,以貨幣方式增資1,586.139911萬元,仍佔鴻益熱電註冊資本的95%;臨杭新市開發建設以貨幣方式增資900萬元,仍佔鴻益熱電註冊資本的5%,鴻益熱電仍為中維化纖控股子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.